Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.

Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M.

Eur J Cancer. 2019 Oct 5;121:202-209. doi: 10.1016/j.ejca.2019.09.001. [Epub ahead of print]

PMID:
31593830
2.

Ancient cattle genomics, origins, and rapid turnover in the Fertile Crescent.

Verdugo MP, Mullin VE, Scheu A, Mattiangeli V, Daly KG, Maisano Delser P, Hare AJ, Burger J, Collins MJ, Kehati R, Hesse P, Fulton D, Sauer EW, Mohaseb FA, Davoudi H, Khazaeli R, Lhuillier J, Rapin C, Ebrahimi S, Khasanov M, Vahidi SMF, MacHugh DE, Ertuğrul O, Koukouli-Chrysanthaki C, Sampson A, Kazantzis G, Kontopoulos I, Bulatovic J, Stojanović I, Mikdad A, Benecke N, Linstädter J, Sablin M, Bendrey R, Gourichon L, Arbuckle BS, Mashkour M, Orton D, Horwitz LK, Teasdale MD, Bradley DG.

Science. 2019 Jul 12;365(6449):173-176. doi: 10.1126/science.aav1002.

PMID:
31296769
3.

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M.

Ann Oncol. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086.

4.

New data for the Early Upper Paleolithic of Kostenki (Russia).

Dinnis R, Bessudnov A, Reynolds N, Devièse T, Pate A, Sablin M, Sinitsyn A, Higham T.

J Hum Evol. 2019 Feb;127:21-40. doi: 10.1016/j.jhevol.2018.11.012. Epub 2018 Dec 19.

PMID:
30777356
5.

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Leary A, Le Tourneau C, Varga A, Sablin MP, Gomez-Roca C, Guilbaud N, Petain A, Pavlyuk M, Delord JP.

Invest New Drugs. 2019 Aug;37(4):693-701. doi: 10.1007/s10637-018-0688-4. Epub 2018 Dec 14.

6.

Dogs accompanied humans during the Neolithic expansion into Europe.

Ollivier M, Tresset A, Frantz LAF, Bréhard S, Bălăşescu A, Mashkour M, Boroneanţ A, Pionnier-Capitan M, Lebrasseur O, Arbogast RM, Bartosiewicz L, Debue K, Rabinovich R, Sablin MV, Larson G, Hänni C, Hitte C, Vigne JD.

Biol Lett. 2018 Oct 17;14(10). pii: 20180286. doi: 10.1098/rsbl.2018.0286.

7.

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.

Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, Berton-Rigaud D, Sablin MP, Lesoin A, Rezai K, Lokiec FM, Lhomme C, Bosq J, Bexon AS, Gilles EM, Proniuk S, Dieras V, Jackson DM, Zukiwski A, Italiano A.

PLoS One. 2018 Oct 10;13(10):e0204973. doi: 10.1371/journal.pone.0204973. eCollection 2018.

8.

Ancient human parvovirus B19 in Eurasia reveals its long-term association with humans.

Mühlemann B, Margaryan A, Damgaard PB, Allentoft ME, Vinner L, Hansen AJ, Weber A, Bazaliiskii VI, Molak M, Arneborg J, Bogdanowicz W, Falys C, Sablin M, Smrčka V, Sten S, Tashbaeva K, Lynnerup N, Sikora M, Smith DJ, Fouchier RAM, Drosten C, Sjögren KG, Kristiansen K, Willerslev E, Jones TC.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):7557-7562. doi: 10.1073/pnas.1804921115. Epub 2018 Jul 2.

9.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

10.

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.

Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I.

Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.

PMID:
29331751
11.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O.

Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7.

12.

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

Fayette J, Guigay J, Le Tourneau C, Degardin M, Peyrade F, Neidhardt EM, Sablin MP, Even C, Orlandini F, Juzyna B, Bellera C.

Oncotarget. 2017 Mar 4;8(31):51830-51839. doi: 10.18632/oncotarget.15901. eCollection 2017 Aug 1.

13.

Three-Dimensional Geometric Morphometric Analysis of Fossil Canid Mandibles and Skulls.

Drake AG, Coquerelle M, Kosintsev PA, Bachura OP, Sablin M, Gusev AV, Fleming LS, Losey RJ.

Sci Rep. 2017 Aug 25;7(1):9508. doi: 10.1038/s41598-017-10232-1.

14.

Stable isotopes reveal diet shift from pre-extinction to reintroduced Przewalski's horses.

Kaczensky P, Burnik Šturm M, Sablin MV, Voigt CC, Smith S, Ganbaatar O, Balint B, Walzer C, Spasskaya NN.

Sci Rep. 2017 Jul 20;7(1):5950. doi: 10.1038/s41598-017-05329-6.

15.

[Cell cycle inhibitors in endocrine receptor positive breast cancer].

Sablin MP, Ricci F, Loirat D, Jobard A, Basse C, Romano E, Le Tourneau C, Dieras V.

Bull Cancer. 2017 Feb;104(2):114-122. doi: 10.1016/j.bulcan.2016.12.005. Epub 2017 Jan 23. French.

PMID:
28126188
16.

Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Pierga JY.

Clin Chem. 2017 Mar;63(3):691-699. doi: 10.1373/clinchem.2016.262337. Epub 2017 Jan 10.

17.

Amy2B copy number variation reveals starch diet adaptations in ancient European dogs.

Ollivier M, Tresset A, Bastian F, Lagoutte L, Axelsson E, Arendt ML, Bălăşescu A, Marshour M, Sablin MV, Salanova L, Vigne JD, Hitte C, Hänni C.

R Soc Open Sci. 2016 Nov 9;3(11):160449. doi: 10.1098/rsos.160449. eCollection 2016 Nov.

18.

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C.

Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666.

PMID:
27993804
19.

Spondylosis deformans in three large canids from the Gravettian Předmostí site: Comparison with other canid populations.

Germonpré M, Losey R, Lázničková-Galetová M, Galeta P, Sablin MV, Latham K, Räikkönen J.

Int J Paleopathol. 2016 Dec;15:83-91. doi: 10.1016/j.ijpp.2016.08.007. Epub 2016 Sep 3.

PMID:
29539558
20.

Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.

Guillot-Delost M, Guilleré L, Berger F, Ventre A, Michea P, Sirven P, Pattarini L, Scholer-Dahirel A, Kebir FZ, Huerre M, Chouchane-Mlik O, Lappartient E, Rodriguez J, Jouffroy T, Klijanienko J, Nicolas A, Sastre-Garau X, Honorio S, Mosseri V, Le Peltier N, Sablin MP, Le Tourneau C, Tartour É, Badoual C, Soumelis V.

Oncoimmunology. 2016 Jun 7;5(7):e1179414. doi: 10.1080/2162402X.2016.1179414. eCollection 2016 Jul.

21.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Hamy AS, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2016 Jul 7;11(7):e0159123. doi: 10.1371/journal.pone.0159123. eCollection 2016.

22.

Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.

Sablin MP, Dubot C, Klijanienko J, Vacher S, Ouafi L, Chemlali W, Caly M, Sastre-Garau X, Lappartient E, Mariani O, Rodriguez J, Jouffroy T, Girod A, Calugaru V, Hoffmann C, Lidereau R, Berger F, Kamal M, Bieche I, Le Tourneau C.

Oncotarget. 2016 Jul 26;7(30):47418-47430. doi: 10.18632/oncotarget.10163.

23.

Genomic and archaeological evidence suggest a dual origin of domestic dogs.

Frantz LA, Mullin VE, Pionnier-Capitan M, Lebrasseur O, Ollivier M, Perri A, Linderholm A, Mattiangeli V, Teasdale MD, Dimopoulos EA, Tresset A, Duffraisse M, McCormick F, Bartosiewicz L, Gál E, Nyerges ÉA, Sablin MV, Bréhard S, Mashkour M, Bălăşescu A, Gillet B, Hughes S, Chassaing O, Hitte C, Vigne JD, Dobney K, Hänni C, Bradley DG, Larson G.

Science. 2016 Jun 3;352(6290):1228-31. doi: 10.1126/science.aaf3161. Epub 2016 Jun 2.

24.

Synchronous genetic turnovers across Western Eurasia in Late Pleistocene collared lemmings.

Palkopoulou E, Baca M, Abramson NI, Sablin M, Socha P, Nadachowski A, Prost S, Germonpré M, Kosintsev P, Smirnov NG, Vartanyan S, Ponomarev D, Nyström J, Nikolskiy P, Jass CN, Litvinov YN, Kalthoff DC, Grigoriev S, Fadeeva T, Douka A, Higham TF, Ersmark E, Pitulko V, Pavlova E, Stewart JR, Węgleński P, Stankovic A, Dalén L.

Glob Chang Biol. 2016 May;22(5):1710-21. doi: 10.1111/gcb.13214. Epub 2016 Feb 25.

PMID:
26919067
25.

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2015 Dec 18;10(12):e0144359. doi: 10.1371/journal.pone.0144359. eCollection 2015. Erratum in: PLoS One. 2016;11(7):e0159123.

26.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators.

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

PMID:
26342236
27.

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy.

Baulies S, Belin L, Mallon P, Senechal C, Pierga JY, Cottu P, Sablin MP, Sastre X, Asselain B, Rouzier R, Reyal F.

Br J Cancer. 2015 Jun 30;113(1):30-6. doi: 10.1038/bjc.2015.174. Epub 2015 Jun 16.

28.

Population genomics of Bronze Age Eurasia.

Allentoft ME, Sikora M, Sjögren KG, Rasmussen S, Rasmussen M, Stenderup J, Damgaard PB, Schroeder H, Ahlström T, Vinner L, Malaspinas AS, Margaryan A, Higham T, Chivall D, Lynnerup N, Harvig L, Baron J, Della Casa P, Dąbrowski P, Duffy PR, Ebel AV, Epimakhov A, Frei K, Furmanek M, Gralak T, Gromov A, Gronkiewicz S, Grupe G, Hajdu T, Jarysz R, Khartanovich V, Khokhlov A, Kiss V, Kolář J, Kriiska A, Lasak I, Longhi C, McGlynn G, Merkevicius A, Merkyte I, Metspalu M, Mkrtchyan R, Moiseyev V, Paja L, Pálfi G, Pokutta D, Pospieszny Ł, Price TD, Saag L, Sablin M, Shishlina N, Smrčka V, Soenov VI, Szeverényi V, Tóth G, Trifanova SV, Varul L, Vicze M, Yepiskoposyan L, Zhitenev V, Orlando L, Sicheritz-Pontén T, Brunak S, Nielsen R, Kristiansen K, Willerslev E.

Nature. 2015 Jun 11;522(7555):167-72. doi: 10.1038/nature14507.

PMID:
26062507
29.

Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S.

World J Hepatol. 2015 Apr 28;7(6):910-5. doi: 10.4254/wjh.v7.i6.910.

30.

The spectrum of clinical trials aiming at personalizing medicine.

Le Tourneau C, Kamal M, Alt M, Verlingue L, Servois V, Sablin MP, Servant N, Paoletti X.

Chin Clin Oncol. 2014 Jun;3(2):13. doi: 10.3978/j.issn.2304-3865.2014.05.02.

31.

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.

Fabre C, Gobbi M, Ezzili C, Zoubir M, Sablin MP, Small K, Im E, Shinwari N, Zhang D, Zhou H, Le Tourneau C.

Cancer Chemother Pharmacol. 2014 Nov;74(5):1057-64. doi: 10.1007/s00280-014-2583-9. Epub 2014 Sep 13.

PMID:
25217392
32.

Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.

Verlingue L, Alt M, Kamal M, Sablin MP, Zoubir M, Bousetta N, Pierga JY, Servant N, Paoletti X, Le Tourneau C.

Per Med. 2014 Jul;11(5):545-558. doi: 10.2217/pme.14.30.

PMID:
29758779
33.

Craniomandibular trauma and tooth loss in northern dogs and wolves: implications for the archaeological study of dog husbandry and domestication.

Losey RJ, Jessup E, Nomokonova T, Sablin M.

PLoS One. 2014 Jun 18;9(6):e99746. doi: 10.1371/journal.pone.0099746. eCollection 2014.

34.

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma.

Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B, Sastre X, Vincent-Salomon A, Tardivon A, Thibault F, Pierga JY, Cottu P, Sablin MP, Rouzier R, Malhaire C, Mallon P, Reyal F.

Br J Cancer. 2014 Apr 29;110(9):2195-200. doi: 10.1038/bjc.2014.143. Epub 2014 Apr 8.

35.

Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.

Le Tourneau C, Paoletti X, Coquan E, Sablin MP, Zoubir M, Tannock IF.

J Clin Oncol. 2014 Jan 20;32(3):260-3. doi: 10.1200/JCO.2013.53.5518. Epub 2013 Dec 2. No abstract available.

PMID:
24297942
36.

Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.

Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S, Sablin MP, Le Tourneau C.

Eur J Cancer. 2014 Feb;50(3):638-48. doi: 10.1016/j.ejca.2013.10.016. Epub 2013 Nov 17. Review.

PMID:
24256808
37.

Complete mitochondrial genomes of ancient canids suggest a European origin of domestic dogs.

Thalmann O, Shapiro B, Cui P, Schuenemann VJ, Sawyer SK, Greenfield DL, Germonpré MB, Sablin MV, López-Giráldez F, Domingo-Roura X, Napierala H, Uerpmann HP, Loponte DM, Acosta AA, Giemsch L, Schmitz RW, Worthington B, Buikstra JE, Druzhkova A, Graphodatsky AS, Ovodov ND, Wahlberg N, Freedman AH, Schweizer RM, Koepfli KP, Leonard JA, Meyer M, Krause J, Pääbo S, Green RE, Wayne RK.

Science. 2013 Nov 15;342(6160):871-4. doi: 10.1126/science.1243650.

38.

Holarctic genetic structure and range dynamics in the woolly mammoth.

Palkopoulou E, Dalén L, Lister AM, Vartanyan S, Sablin M, Sher A, Edmark VN, Brandström MD, Germonpré M, Barnes I, Thomas JA.

Proc Biol Sci. 2013 Sep 11;280(1770):20131910. doi: 10.1098/rspb.2013.1910. Print 2013 Nov 7.

39.

Burying dogs in ancient Cis-Baikal, Siberia: temporal trends and relationships with human diet and subsistence practices.

Losey RJ, Garvie-Lok S, Leonard JA, Katzenberg MA, Germonpré M, Nomokonova T, Sablin MV, Goriunova OI, Berdnikova NE, Savel'ev NA.

PLoS One. 2013 May 17;8(5):e63740. doi: 10.1371/journal.pone.0063740. Print 2013.

40.

Species-specific responses of Late Quaternary megafauna to climate and humans.

Lorenzen ED, Nogués-Bravo D, Orlando L, Weinstock J, Binladen J, Marske KA, Ugan A, Borregaard MK, Gilbert MT, Nielsen R, Ho SY, Goebel T, Graf KE, Byers D, Stenderup JT, Rasmussen M, Campos PF, Leonard JA, Koepfli KP, Froese D, Zazula G, Stafford TW Jr, Aaris-Sørensen K, Batra P, Haywood AM, Singarayer JS, Valdes PJ, Boeskorov G, Burns JA, Davydov SP, Haile J, Jenkins DL, Kosintsev P, Kuznetsova T, Lai X, Martin LD, McDonald HG, Mol D, Meldgaard M, Munch K, Stephan E, Sablin M, Sommer RS, Sipko T, Scott E, Suchard MA, Tikhonov A, Willerslev R, Wayne RK, Cooper A, Hofreiter M, Sher A, Shapiro B, Rahbek C, Willerslev E.

Nature. 2011 Nov 2;479(7373):359-64. doi: 10.1038/nature10574.

41.

[PI3K-AKT-mTOR pathway and cancer].

Coutte L, Dreyer C, Sablin MP, Faivre S, Raymond E.

Bull Cancer. 2012 Feb 1;99(2):173-80. doi: 10.1684/bdc.2011.1384. Review. French.

42.

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.

Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E, Faivre S.

Target Oncol. 2011 Jun;6(2):119-24. doi: 10.1007/s11523-011-0177-6. Epub 2011 Apr 28. Review.

PMID:
21533544
43.

Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.

Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E.

Clin Cancer Res. 2011 Jul 1;17(13):4504-12. doi: 10.1158/1078-0432.CCR-10-1708. Epub 2011 Apr 29.

44.

[Targeted therapies in colorectal cancer].

Sablin MP, Dreyer C, Colichi C, Bouattour M, Faivre S.

Rev Prat. 2010 Oct 20;60(8):1094-9. French.

PMID:
21197741
45.

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

Serova M, Bieche I, Sablin MP, Pronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E.

Br J Cancer. 2011 Jan 18;104(2):272-80. doi: 10.1038/sj.bjc.6606063. Epub 2010 Dec 21.

46.

Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.

Faivre S, Sablin MP, Dreyer C, Raymond E.

Endocrinol Metab Clin North Am. 2010 Dec;39(4):811-26. doi: 10.1016/j.ecl.2010.09.006. Review.

PMID:
21095547
47.

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1005-15. doi: 10.1517/17425255.2010.506872. Review.

PMID:
20636223
48.

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E.

Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Review.

PMID:
20569080
49.

Sequential sorafenib and sunitinib for renal cell carcinoma.

Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B.

J Urol. 2009 Jul;182(1):29-34; discussion 34. doi: 10.1016/j.juro.2009.02.119. Epub 2009 May 17.

PMID:
19447417
50.

[Colorectal cancers: prognostic and predictive factors of response to treatment].

Sablin MP, Italiano A, Spano JP.

Bull Cancer. 2009 Apr;96(4):417-23. doi: 10.1684/bdc.2009.0781. Review. French.

Supplemental Content

Loading ...
Support Center